Roel Q. J. Schaapveld

InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands.

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek is a scientific research institute and a specialist clinic. The firm’s areas of research are including fundamental, clinical and translational cancer research. The company was founded in 1916 and is headquartered in Amsterdam, Netherlands.

Kreatech Biotechnology BV provides diagnostics detection products. It develops tools for labeling and detection of DNA, RNA, and proteins molecules. The company's products are used in the areas of Oncology, Haematology, and Pre-natal diagnostics. It offers services to the drug discovery, pharmaceutical, diagnostics, and life science companies. Kreatech Biotechnology was founded by Volkers Herman in 1990 and is headquartered in Amsterdam, the Netherlands.

Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA.

Kempen & Co. NV provides financial services to professional investors. The company's clients include institutional investors, companies, financial institutions, public & semi-public institutions, foundations and high-net-worth private clients. The company was founded in July 1903 by A. J. Kempen and M. D. de Lange and is headquartered in Amsterdam, The Netherlands.